Drug & compound design and optimization

When pursuing insights on critical disease and biological targets, or trying to understand specific molecular mechanisms that cause complex diseases, significant resources are needed to effectively collect, normalize, and analyze data from multiple sources. Drawing on Elsevier’s passion for the curation and classification of life science data, the Professional Services Group (PSG) provides bespoke analysis and insights in the area of scientific compound design and optimization:

Target-related custom reports

The Professional Services Group helps to accelerate early discovery activities by providing access to critical disease and target overview information leading to the prioritization of certain research focus areas.

PSG custom reports answer key research questions such as:

Disease focus

heart - pictogram

  • What new targets may exist to treat a specific disease
  • How can side effects be reduced?
  • How does each target score based on pathway activation, gene expression, and overall literature analysis?

Target focus

target focus - pictogram

  • Which diseases might this target treat?
  • What are the potential adverse events and drug interactions?
  • Are there known molecules that are likely to be test molecules?

Professional services solutions

PSG’s target-related custom reports offer solutions to common resource challenges, whether there are gaps in internal data integration and analysis, or there’s a need for more comprehensive data outside of open source databases. PSG services include the following custom reports:

Target prioritization report: custom report calculating primary scores for each target within the signaling pathway, and an overall global prioritization score for each target.

Target overview report: detailed report highlighting all known target-related evidence including indication and route, mode of action, pathway, closely related targets, potential indications, and known active compounds.

Target safety assessment report: detailing the signaling pathway, biological consequences of pharmacological inhibition, protein structure, and potential toxicities based on methods of action.

Papilloma virus - 3d rendered illustration

Key outcomes

Insights - pictogram


Critical insights into the biology of diseases and targets

Evidence - pictogram


Summary evidence in support of new and existing research hypotheses

Prioritization - pictogram


Identification and prioritization of research focus areas through a comprehensive compilation of all available evidence

Disease pathway & analysis

Based on the analysis of biological pathways in humans and animals, and other testing data, PSG provides insights into the potential chemical risk of specific compounds and the underlying molecular mechanisms that might cause complex diseases.

PSG custom reports answer key research questions such as:

Disease pathway analysis

Analysis - pictogram

  • What are the right key cells to target?
  • Which proteins are relevant in a particular disease?
  • What other functionally-related molecules might be associated with a candidate biomarker?

Adverse outcome pathway (AOP):

Outcome - Pictogram

  • What are the biomarkers on the path to toxicity?
  • Which molecular mechanisms are linked to disease outcomes?

Professional services solutions

Whether there is a need for sourcing and linking comprehensive datasets, or there are resource gaps specific to consolidating and integrating pathway data, PSG can provide the following solutions:

Disease pathway analysis: Interactive analytical and visualization tools enabling researchers to explore molecular interactions and cause/effect relationships, while offering insights into the underlying biology affecting development, disease progression, and drug responsiveness.

Adverse outcome pathway (AOP): Annotated pathway using Elsevier’s proprietary database of biological relationships extracted from Natural Language Processes (NLP) technology.

Optometry Corneal Topographer Showing an Eye and Cornea on Screen

Key outcomes

Insights - pictogram


Critical insights into the biology of diseases and targets

Results - Pictogram


Robust and reliabscoring, which is embedded le results based on confidence in Elsevier’s Text Mining capability

Identification - pictogram


Identification of potential novel targets

Scientific opportunity analysis

PSG uses competitive intelligence to inform decision-making processes for researchers entering particular fields – providing key information on targets, compounds, competitive activity, patents, key contributors, and potential collaborators in the space.

PSG custom reports answer key research questions such as:

Competitive intelligence

Analysis - pictogram

  • Which targets are currently being studied?
  • What are the leading compounds in the field?
  • Which patents of importance currently exist?
  • Which compounds are referenced in which patents?

Market assessment:

Outcome - Pictogram

  • Which experts are not collaborating with a competitor?
  • With whom can I partner?
  • How much funding is dedicated to a particular area of research, and how much progress has been made?

Professional services solutions

PSG’s scientific opportunity analysis solutions help organizations thoroughly assess pertinent factors and levers that implicate and drive R&D strategies and priorities. By gathering, analyzing, and interpreting Elsevier- and 3rd party- data, PSG serves as a steward of knowledge and market insights through the following tools and solutions:

Custom reports: Detailed information providing subject-based insights on key markets contributors and potential collaborators; evaluation of data models; existing clinical trials and program funding; and research trends and progress.

Custom workflows & dashboards: Personalized look-up and automatic-refresh tools providing researchers with real-time updates on new discoveries, threats, and opportunities (i.e. compounds and patents) in the market.

Discussing new opportunities for business growth

Key outcomes

Access - Pictogram


Real-time information on relevant market changes that help drive strategic and timely decisions

Efficiency - pictogram


Smart resource investment based on a thorough understanding of disease state and overall opportunity

Acceleration - pictogram


Research advancement through identification of key collaborators, sponsors, and relevant patient clinics